Oxford medical case reports · 2025
Case report: the challenges of psychogenic polydipsia.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Raha Anirban, Mordekar Aparna
Аннотация
AIM: We describe a case report of a 71-year-old with a long history of Paranoid Schizophrenia presenting with psychogenic polydipsia.
BACKGROUND: Psychogenic polydipsia is a rare and challenging complication of Paranoid Schizophrenia. Research is limited with regards to how to treat this effectively, however the management normally involves fluid restriction and behavioural therapy.
METHOD: We looked through his history and liaised with multiple specialities to compile this report.
RESULT: This patient has long history of psychogenic polydipsia. More recently he presented with his chronic hyponatremia. To aid reduction of his hyponatraemia, his duloxetine was stopped, and his olanzapine dose reduced.
CONCLUSIONS: There is evidence in the role of naltrexone in reducing compulsive drinking. We trialled this at 25 mg and the patient's drinking behaviour has reduced in the community.
BACKGROUND: Psychogenic polydipsia is a rare and challenging complication of Paranoid Schizophrenia. Research is limited with regards to how to treat this effectively, however the management normally involves fluid restriction and behavioural therapy.
METHOD: We looked through his history and liaised with multiple specialities to compile this report.
RESULT: This patient has long history of psychogenic polydipsia. More recently he presented with his chronic hyponatremia. To aid reduction of his hyponatraemia, his duloxetine was stopped, and his olanzapine dose reduced.
CONCLUSIONS: There is evidence in the role of naltrexone in reducing compulsive drinking. We trialled this at 25 mg and the patient's drinking behaviour has reduced in the community.